Business Wire

LG Chem Is Targeting to Penetrate the Solar Panel Frame Market

19.10.2021 03:00:00 EEST | Business Wire | Press release

Share

LG Chem (KRX: 051910) has developed a plastic material that can replace the metal in solar panel frames for the first time in Korea and starts full-scale market penetration.

LG Chem announced that the Company has developed ‘LUPOY EU5201’, a PC/ASA flame retardant material that maintains the material shape even during temperature changes due to its low thermal expansion levels, using their proprietary technology and manufacturing method.

* PC/ASA: Engineering plastic with enhanced physical properties made by mixing ASA (Acrylonitrile Styrene Acrylate) resins with polycarbonate as a base

Solar panel frames are located at the edge of solar panels to protect and support the panel from external impact. Heat resistance and strong durability against corrosion are required as the materials are exposed outside for a long time, such as on exterior walls or the roof where there is direct sunlight. Solar panel frames account for about 10% of solar panels, and are mainly made of aluminum alloy.

The ‘LUPOY EU5201’, developed by LG Chem, is a high-performance engineering plastic material that supplements the mechanical properties of general plastics by adding glass fiber to polycarbonate compounds.

It has the same level of durability as existing aluminum, but is half the weight and has excellent price competitiveness. Also, it has excellent dimensional stability that maintains its shape even in temperature changes, so it is not easily deteriorated or deformed by the external environment. The chemical decomposition caused by ultraviolet rays exposure has been reduced, which has significantly improved the lifespan of the product compared to general plastics, and the color remains the same even after long-term exposure to ultraviolet rays.

If aluminum is replaced with LG Chem's new engineering plastic material, the weight of the solar panel is expected to decrease dramatically and material cost can also be reduced. This can bring increased convenience during transportation and installation.

LG Chem has PCR PC (Post-Consumer Recycled Polycarbonate) development technology that recycles plastics used by general consumers, so the Company can also produce eco-friendly low-carbon products using high-content PCR raw materials at the request of customers. The Company also plans to review ways to collect the solar panel frame that will be discarded in the future and reproduce them into PCR PC.

LG Chem has secured mass production capability during the first half of this year and started selling products in full-scale in the third quarter. Starting with the supply for solar panel frames, the Company plans to expand the application of materials to interior and exterior materials of automobiles in the future.

Steven Kim, Leader of the Engineering Materials Division at LG Chem, stated, “Solar panel frames made of plastic have many advantages that differentiate them from existing frames, such as ease of installation, and therefore have great market potential. Based on the world's best compounding technology, LG Chem plans to lead the rapidly growing solar material market through continuous R&D and investment into mass production capabilities.”

LG Chem declared ‘carbon-neutral growth by 2050’ last year, the first company to do so in the domestic petrochemical industry, and is promoting RE100, which produces products using renewable energy at all workplaces around the world. LG Chem plans to accelerate carbon-neutral growth through the transition to renewable energy and contribute to the development of renewable energy industry such as solar power through the development of LUPOY EU5201 product.

About LG Chem

LG Chem, Ltd. is Korea’s largest diversified chemical company which operates three main business units: Petrochemicals, Advanced Materials, Life Sciences. The chemical business manufactures a wide range of products, from petrochemical goods to high-value added plastics. It also extends its chemical expertise into high-tech areas such as electronic & battery materials and drugs & vaccines. Throughout multiple production facilities and an extensive distribution network, LG Chem strives to become a leading global company. For more information, please visit the LG Chem website at www.lgchem.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

LG Chem, Ltd.
Sangkyu Choi, Manager
+82-2-3773-7869
choisg@lgchem.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye